Therefore, only people with chronic CVD would need to be considered for conversion to high-dose, high-intensity statin (atorvastatin 80 mg). There is no time restriction on implementing recommendation 1.3.30 with existing patients. There is no anticipated increase in workload as discussion could take place at the time of their next annual review. Further resources There are further NICE resources that may help to support implementation. The UK National Screening Committee has agreed to reflect the 10% risk threshold in The NHS Health Check programme in line with the NICE recommendations. NICE produces indicators annually for use in the Quality and Outcomes Framework (QOF) for the UK. The process for this and the NICE menu can be found on NICE's Quality and Outcomes Framework indicator webpage. Uptake data about guideline recommendations and quality standard measures are available. Recommendations for research The guideline development group has made the following recommendations for research. The guideline development group's full set of research recommendations is in the full guideline. 1 Simplifying risk assessment What is the effectiveness of age alone and other routinely available risk factors compared with the formal structured multifactorial risk assessment to identify people at high risk of developing cardiovascular disease (CVD)? Why this is important Current risk assessment tools rely on a complex set of data derived from demographic, lifestyle, physiological and biochemical parameters. The principal determinant of CVD risk is age, and this may be sufficient to identify high-risk populations. However, focusing on age alone may result in people being missed who are at higher risk as a result of other factors that do not require access to intensive resources, such as smoking status, family history and deprivation. It is important therefore to assess age against validated simplified and complex CVD risk tools when predicting people at high risk. 